文献速递精神分裂症与精神病性障碍物质与行为成瘾

精神分裂症共病物质使用障碍的心理社会干预:系统综述与Meta分析

Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

该系统综述与Meta分析纳入35项RCT共4136名精神分裂症共病物质使用障碍患者,评估心理社会干预对比对照组的疗效。结果显示干预对总体症状仅呈极小效应(SMD -0.11),对各类物质使用减少无差异(SMD -0.01),仅尼古丁使用显示小效应,提示现有干预效果有限。

要点

  • 心理社会干预对总体症状仅呈极小效应(SMD -0.11),证据置信度低。
  • 干预对减少各类物质使用无差异(SMD -0.01),仅尼古丁使用显示小效应。
  • 现有干预对精神分裂症共病物质使用障碍效果有限,亟需开发更有效策略。

核心结论

  • 现有心理社会干预对精神分裂症共病物质使用障碍患者减少症状获益有限,对减少物质使用无效,仅尼古丁使用例外。

研究设计与样本

  • 系统综述与随机效应配对Meta分析,检索Cochrane精神分裂症组注册库至2025年1月13日。
  • 纳入35项RCT共4136名成人患者,其中29项试验3831人纳入配对Meta分析。
  • 报告3748名参与者中951人(25.4%)为女性,平均年龄37.2岁(范围20.6-57.5)。

主要发现

  • 减少总体症状方面干预组有极小效应(SMD -0.11;95%CI -0.27至0.05;13项试验;低置信度),主要由尼古丁研究驱动。
  • 减少所有类型物质使用方面干预组与对照组无差异(SMD -0.01;95%CI -0.21至0.18;8项试验;中等置信度)。
  • 酒精、大麻、苯丙胺及其他兴奋剂分别分析均显示无效应,尼古丁使用显示小效应。

关键数值与推荐

  • 主要结局为治疗后用验证量表测量的总体症状和物质使用减少。
  • 采用GRADE方法评估证据置信度。

临床怎么用

  • 临床应认识到现有心理社会干预对共病患者的症状和物质使用改善有限。
  • 针对尼古丁使用的干预可能有一定效果,可优先考虑。
  • 需开发更有效的治疗策略以改善该人群预后。

局限性

  • 总体症状分析证据置信度低。
  • 物质使用减少分析仅纳入8项试验。
  • 该特殊群体常被临床试验和系统综述排除,可能限制证据代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Substance use disorder (SUD) is commonly found in individuals with schizophrenia, with a high co-occurrence rate of approximately 41.7%. Despite this high prevalence, people with both schizophrenia and SUD are frequently excluded from clinical trials and systematic reviews; this special group is particularly challenging to treat and imposes a significant economic burden on health care systems. OBJECTIVE: To evaluate the efficacy, acceptability, and tolerability of psychological and psychosocial interventions in patients with schizophrenia and co-occurring SUD. DATA SOURCES: The Cochrane Schizophrenia Group registry was searched up to January 13, 2025. Data analysis was performed from March to April 2025. STUDY SELECTION: Randomized clinical trials (RCTs) examining psychological and psychosocial interventions compared with control groups in adults with schizophrenia and concomitant SUD were identified. No restrictions were applied regarding the type of substance used, including alcohol, cannabis, nicotine, and stimulants, such as amphetamines. DATA EXTRACTION AND SYNTHESIS: A systematic review and random-effect pairwise meta-analyses were conducted to estimate standardized mean differences (SMD) with 95% confidence intervals and were reported following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. Confidence in the estimate was assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. MAIN OUTCOMES AND MEASURES: The primary outcomes were overall symptoms and substance use reduction measured by validated scales at posttreatment. RESULTS: A total of 35 RCTs were included (4136 participants), with 29 trials involving 3831 participants contributing to pairwise meta-analyses comparing psychological and psychosocial interventions with control conditions. Among the 3748 participants with reported sex, 951 (25.4%) were female, and mean (range) age was 37.2 (20.6-57.5) years. A very small effect favoring the intervention group was observed in reducing overall symptoms (SMD, -0.11; 95% CI, -0.27 to 0.05; 13 trials; low confidence in the estimate), mainly driven by nicotine studies. No difference was found between intervention and control groups in reducing all types of substance use (SMD, -0.01; 95% CI, -0.21 to 0.18; 8 trials; moderate confidence). When considered separately, alcohol, cannabis, amphetamines, and other stimulants showed similar no-effect results, while nicotine use indicated a small effect. CONCLUSION AND RELEVANCE: The findings of this systematic review and meta-analysis suggest that current psychological and psychosocial interventions provide limited benefit in reducing symptoms and no effect in reducing substance use in individuals with schizophrenia and SUD compared to control conditions, with the exception of nicotine use, highlighting the urgent need to develop more effective treatment strategies.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Salahuddin NH, Herlitzius E, Schütz A, et al. Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2026. PMID: 41637064. doi:10.1001/jamapsychiatry.2025.4390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。